復鋭醫療科技(01696.HK)預計中期溢利同比增逾190%
格隆匯7月5日丨復鋭醫療科技(01696.HK)公佈,相較2020年同期,集團預期於截至2021年6月30日止6個月的收益錄得大幅上升逾73%,及預期於該期間的溢利增加逾190%。
該期間的預期收益及溢利大幅度上升,主要歸因於集團(i)業務遍佈全球超過90多個國家及地區,有助於在動態變化的市場中保持敏鋭度和靈活度;(ii)在兩個主要市場的強勁增長:北美市場及中國市場;(iii)彈性管理戰略,在疫情期間採取積極的人才政策,保持公司團隊穩健發展;(iv)多維度產品線及渠道在全球醫美市場中的拓展與協同;(v)強大的研發能力,支持持續推出新技術及新產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.